Nexgard Spectra

afoxolaner / milbemycin oxime

Opinion

On 18 July 2019, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion*, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Nexgard Spectra. The marketing authorisation holder for this veterinary medicinal product is MERIAL.

Nexgard Spectra is currently authorised as chewable tablets for the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease, angiostrongylosis and/or treatment of gastrointestinal nematode infestations is indicated. The product is also indicated for the treatment of demodicosis and sarcoptic mange.

This variation was to add a new therapeutic indication: prevention of establishment of thelaziosis (adult Thelazia callipaeda eyeworm infection).

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.


* Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Key facts

Name
Nexgard Spectra
Agency product number
EMEA/V/C/003842
International non-proprietary name (INN) or common name
  • afoxolaner / milbemycin oxime
Species
Dogs
Active substance
  • afoxolaner
  • milbemycin oxime
Date opinion adopted
18/07/2019
Company name
Mérial
Status
Positive
Application type
Post-authorisation

How useful was this page?

Add your rating